AAV2hAQP1: 1 x 10^11 vg/gland (single gland) + AAV2hAQP1: 3 x 10^10 vg/gland (both glands) + AAV2hAQP1: 3 x 10^11 vg/gland (single gland) + AAV2hAQP1: 1 x 10^11 vg/gland (both glands) + AAV2hAQP1: 1 x 10^12 vg/gland (single gland) + AAV2hAQP1: 3 x 10^11 vg/gland (both glands) + AAV2hAQP1: 3 x 10^12 vg/gland (single gland) + AAV2hAQP1: 1 x 10^12 vg/gland (both glands)

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Radiation-Induced Parotid Gland Hypofunction

Conditions

Radiation-Induced Parotid Gland Hypofunction, Xerostomia Due to Radiotherapy, Head and Neck Cancer

Trial Timeline

Jun 30, 2019 → Mar 28, 2023

NCT ID

NCT04043104

About AAV2hAQP1: 1 x 10^11 vg/gland (single gland) + AAV2hAQP1: 3 x 10^10 vg/gland (both glands) + AAV2hAQP1: 3 x 10^11 vg/gland (single gland) + AAV2hAQP1: 1 x 10^11 vg/gland (both glands) + AAV2hAQP1: 1 x 10^12 vg/gland (single gland) + AAV2hAQP1: 3 x 10^11 vg/gland (both glands) + AAV2hAQP1: 3 x 10^12 vg/gland (single gland) + AAV2hAQP1: 1 x 10^12 vg/gland (both glands)

AAV2hAQP1: 1 x 10^11 vg/gland (single gland) + AAV2hAQP1: 3 x 10^10 vg/gland (both glands) + AAV2hAQP1: 3 x 10^11 vg/gland (single gland) + AAV2hAQP1: 1 x 10^11 vg/gland (both glands) + AAV2hAQP1: 1 x 10^12 vg/gland (single gland) + AAV2hAQP1: 3 x 10^11 vg/gland (both glands) + AAV2hAQP1: 3 x 10^12 vg/gland (single gland) + AAV2hAQP1: 1 x 10^12 vg/gland (both glands) is a phase 1 stage product being developed by MeiraGTx for Radiation-Induced Parotid Gland Hypofunction. The current trial status is completed. This product is registered under clinical trial identifier NCT04043104. Target conditions include Radiation-Induced Parotid Gland Hypofunction, Xerostomia Due to Radiotherapy, Head and Neck Cancer.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04043104	Phase 1	Completed	Jun 30, 2019	Mar 28, 2023	Radiation-Induced Parotid Gland Hypofunction

Competing Products

2 competing products in Radiation-Induced Parotid Gland Hypofunction

See all competitors

Product	Company	Stage	Hype Score
Pirfenidone Capsules （400 mg） + Pirfenidone Capsules（600mg） + Pirfenidone Capsules（0mg）	Sun Pharmaceutical	Phase 2/3	65
oxetacaine, aluminium and magnesium hydroxide + oxetacaine + magnesium and aluminium hydroxide	Viatris	Phase 3	74

Other Products from MeiraGTx

AAV RPE65Phase 1/2

AAV - CNGB3Phase 1/2

adeno-associated virus vector AAV- CNGA3Phase 1/2

AAV2hAQP1Phase 1

AAV OPTIRPE65Pre-clinical